These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2517445)

  • 1. Spinocerebellar degeneration and neuropeptides.
    Matsuoka Y; Sakurai N
    Jpn J Med; 1989; 28(6):791-3. PubMed ID: 2517445
    [No Abstract]   [Full Text] [Related]  

  • 2. [Spinocerebellar degeneration and neuropeptides].
    Matsuoka Y; Sakurai N
    Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1705-8. PubMed ID: 2516527
    [No Abstract]   [Full Text] [Related]  

  • 3. [Amine metabolites in cerebrospinal fluids and thyrotropin releasing hormone in spinocerebellar degeneration].
    Arai M
    Rinsho Shinkeigaku; 1988 Jun; 28(6):595-604. PubMed ID: 2466598
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects].
    Filla A; De Michele G; Di Martino L; Mengano A; Iorio L; Maggio MA; Campanella G
    Riv Neurol; 1989; 59(2):83-8. PubMed ID: 2505370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedside and electro-oculographic analysis of abnormal ocular movements in spinocerebellar degenerations: effects of thyrotropin-releasing hormone.
    Yamamoto H; Saito S; Sobue I
    Neurology; 1988 Jan; 38(1):110-4. PubMed ID: 3122069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alteration of CBF and CMRO2 and TRH effects on CBF in spinocerebellar degeneration. The positron emission tomography study].
    Harada K; Fukuyama H; Miyoshi T; Namura Y; Kameyama M
    Rinsho Shinkeigaku; 1988 May; 28(5):563-8. PubMed ID: 3145826
    [No Abstract]   [Full Text] [Related]  

  • 7. [Spinocerebellar degeneration].
    Sugai Y
    Ryoikibetsu Shokogun Shirizu; 2003; (40):272-4. PubMed ID: 14626118
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral thyrotropin-releasing hormone treatment in inherited ataxias.
    Bonuccelli U; Nuti A; Cei G; Rossi G; Grasso L; Martino E; Muratorio A
    Clin Neuropharmacol; 1988 Dec; 11(6):520-8. PubMed ID: 3148366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical manifestations and thyrotropin releasing hormone therapy in cerebellar degenerations.
    Wang HC; Chiu HC
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Mar; 47(3):161-8. PubMed ID: 1848143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of thyrotropin-releasing hormone (TRH) on cerebral blood flow in spinocerebellar degeneration and cerebrovascular disease.
    Izumi Y; Fukuuchi Y; Ishihara N; Imai A; Komatsumoto S
    Tokai J Exp Clin Med; 1995 Dec; 20(4-6):203-8. PubMed ID: 8956461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT.
    Kimura N; Kumamoto T; Masuda T; Nomura Y; Hanaoka T; Hazama Y; Okazaki T; Arakawa R
    J Neurol Sci; 2009 Jun; 281(1-2):93-8. PubMed ID: 19286195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of TRH-T for spinocerebellar degeneration--the relation between clinical features and effect of TRH therapy].
    Waragai M; Ogawara K; Takaya Y; Hayashi M
    Rinsho Shinkeigaku; 1997 Jul; 37(7):587-94. PubMed ID: 9396355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial.
    Mori N; Adachi Y; Takeshima T; Kashiwaya Y; Okada A; Nakashima K
    Intern Med; 1999 May; 38(5):401-6. PubMed ID: 10397076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications.
    Fröhlich E; Wahl R
    Front Neuroendocrinol; 2019 Jan; 52():29-43. PubMed ID: 29935915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of the thyrotropin releasing hormone (TRH) on the motor speech disorder in spinocerebellar degeneration].
    Nozaki Y; Hashimoto M; Ohnishi A; Murai Y; Ogata H; Makishima K
    J UOEH; 1992 Jun; 14(2):173-83. PubMed ID: 1621012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Spinocerebellar degeneration].
    Takayanagi T
    Nihon Naika Gakkai Zasshi; 1993 Mar; 82(3):377-80. PubMed ID: 8315331
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of tartrate thyrotropin-releasing hormone treatment on serum thyrotropin, free triiodothyronine, free thyroxine and prolactin levels in patients with spinocerebellar degeneration.
    Merola B; Colao A; Di Renzo G; Filla A; Campanella G; Lombardi G
    Horm Res; 1992; 38(3-4):160-3. PubMed ID: 1306848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long loop reflex in spinocerebellar degeneration and motor neuron disease--its changes with TRH therapy.
    Touge T; Takeuchi H; Yamada A; Miki H; Nishioka M
    Electromyogr Clin Neurophysiol; 1990; 30(3):131-40. PubMed ID: 2112456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spinocerebellar degenerations].
    Sobue I
    Nihon Naika Gakkai Zasshi; 1984 Oct; 73(10):1415-31. PubMed ID: 6440937
    [No Abstract]   [Full Text] [Related]  

  • 20. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya.
    Ijiro T; Yaguchi A; Yokoyama A; Abe Y; Kiguchi S
    Eur J Pharmacol; 2020 Sep; 882():173271. PubMed ID: 32534077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.